A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
A prognostic model based on cell-cycle control predicts outcome of breast cancer patients
Tekijät: Heli Repo, Eliisa Löyttyniemi, Samu Kurki, Lila Kallio, Teijo Kuopio, Kati Talvinen, Pauliina Kronqvist
Kustantaja: BMC
Julkaisuvuosi: 2020
Journal: BMC Cancer
Tietokannassa oleva lehden nimi: BMC CANCER
Lehden akronyymi: BMC CANCER
Artikkelin numero: ARTN 558
Vuosikerta: 20
Numero: 1
Sivujen määrä: 8
eISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07045-3
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/49345025
Background A prognostic model combining biomarkers of metaphase-anaphase transition of the cell cycle was developed for invasive breast cancer. The prognostic value and clinical applicability of the model was evaluated in comparison with the routine prognosticators of invasive breast carcinoma. Methods The study comprised 1135 breast cancer patients with complete clinical data and up to 22-year follow-up. Regulators of metaphase-anaphase transition were detected immunohistochemically and the biomarkers with the strongest prognostic impacts were combined into a prognostic model. The prognostic value of the model was tested and evaluated in separate patient materials originating from two Finnish breast cancer centers. Results The designed model comprising immunoexpressions of Securin, Separase and Cdk1 identified 8.4-fold increased risk of breast cancer mortality (p < 0.0001). A survival difference exceeding 15 years was observed between the majority (> 75%) of patients resulting with favorable as opposed to unfavorable outcome of the model. Along with nodal status, the model showed independent prognostic impact for all breast carcinomas and for subgroups of luminal, N+ and N- disease. Conclusions The impact of the proposed prognostic model in predicting breast cancer survival was comparable to nodal status. However, the model provided additional information in N- breast carcinoma in identifying patients with aggressive course of disease, potentially in need of adjuvant treatments. Concerning N+, in turn, the model could provide evidence for withholding chemotherapy from patients with favorable outcome.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
